Nightingale Direct Care

05/11/2026

🔬 BREAKING RESEARCH: A September 2024 study identified a unique blood signature in hypermobile Ehlers-Danlos syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD)—bringing us closer than ever to a definitive diagnostic tool.

For years, individuals with hEDS and HSD have faced平均 an average of 10-20 years for diagnosis, countless misdiagnoses, and feeling unheard by healthcare systems. This groundbreaking discovery validates what patients have known all along: these conditions are REAL and have measurable biological markers.

Key takeaways from the research:
✅ Lower levels of complement proteins found in people with hEDS/HSD
✅ Proteomic differences could enable objective diagnosis
✅ May finally bridge the gap between patient symptoms and clinical recognition

As one Clinician noted, "Research is finally catching up to what patients have been telling us for decades."

If you or someone you love lives with hEDS or HSD, this news represents hope for faster diagnosis, better understanding, and improved care pathways.

💙 Share this post to spread awareness and support the EDS/HSD community!

https://nightingaledirect.care

A streamlined platform connecting patients with personalized, direct primary care services to simplify healthcare access.

05/06/2026

How does Spravato work differently than traditional antidepressants?

If you've tried multiple antidepressants without relief, you know how frustrating it can be. Spravato (esketamine) offers a different approach.

Unlike traditional antidepressants that target serotonin or other neurotransmitters, Spravato targets the NMDA receptor in the brain. This unique mechanism may help reset neural pathways associated with depression, particularly for those with treatment-resistant depression.

Spravato is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal thoughts. It's administered as a nasal spray in a certified healthcare setting, where you'll be monitored for about two hours after each treatment.

Many patients report experiencing relief within days to weeks, though individual results vary. Spravato is typically used alongside an oral antidepressant.

If traditional depression treatments haven't worked for you, Spravato may be worth exploring. Reach out to a healthcare provider to learn if esketamine therapy could be right for you.

05/04/2026

Could your depression treatment be working differently than you expect?

Unlike traditional antidepressants that target serotonin, Spravato (esketamine) works uniquely on the NMDA receptor in your brain — part of the glutamate system that's believed to play a key role in mood regulation. This innovative approach offers hope for those living with treatment-resistant depression or major depressive disorder with suicidal thoughts.

Because Spravato is an FDA-approved ketamine therapy option, it administered under the care of a qualified Clinician in a supervised clinical setting. Many patients report experiencing relief within hours or days — not weeks.

If you've tried multiple antidepressants without success, you may be a candidate for esketamine treatment.

📩 Contact us today to learn if Spravato could be right for you. Always consult a healthcare provider to discuss your options.

04/29/2026

04/29/2026

EDS ECHO at The Ehlers-Danlos Society is delighted to announce applications are now open for licensed physical therapists/physiotherapists wanting to learn how to use principles of neuroplasticity to retrain alignment and stability in hypermobile patients.

The EDS ECHO Finding Functional Foundations (FFF)™ course approach uses biofeedback and specific cuing methods, to retrain the brain allowing patients to:

🟢Improve faulty proprioception
🟢Strengthen deep stabilizers
🟢Learn proper physical alignment, and; a
🟢Apply those skills to functional movement.

This leads to decreased pain and neurological symptoms, and improved function.

The course is cotaught by Susan Chalela, PT, and Prof. Leslie Russek, PT, PhD, blending their extensive clinical experience and evidence-based approaches. The course is available to the following licensed healthcare professionals who are currently treating patients with EDS or HSD:

- Licensed Physical Therapists/Physiotherapists and Physical Therapy Assistants

- Licensed Occupational Therapists and Occupational Therapy Assistants

- Licensed Osteopaths

- Licensed Chiropractors

This course runs from September to December 2026. Places are limited to 50 participants per course and are on a first-come, first-served basis.

Learn more about this course and apply here: https://www.ehlers-danlos.com/eds-echo-finding-functional-foundations-registration/

04/29/2026

For millions with Ehlers-Danlos Syndrome, diagnosis has taken 10–15 years of dismissed symptoms and mounting frustration.

That just changed.

Harvard Medical School & Brigham and Women's Hospital just partnered with The Ehlers-Danlos Society to transform how EDS is diagnosed and managed—starting with primary care.

New diagnostic criteria drop December 1, 2026. The goal: earlier recognition, coordinated care, and an end to patients being told "it's just anxiety."

73% of EDS patients say they've second-guessed their own pain after clinician skepticism. That ends here.

If you or someone you love is navigating EDS or hypermobility spectrum disorder, comment below or tap the link to learn more about what this means for care ahead.

🗓️ May Awareness Month is right around the corner—help us make the invisible visible.
https://nightingaledirect.care

A streamlined platform connecting patients with personalized, direct primary care services to simplify healthcare access.

04/27/2026

When traditional depression treatments haven't provided relief, Spravato (esketamine) may offer a different approach. Unlike conventional antidepressants that target serotonin or other neurotransmitters, Spravato works by blocking the NMDA receptor in the brain—a mechanism believed to help restore synaptic connections and improve mood regulation.

This FDA-approved ketamine therapy nasal spray is specifically designed for treatment-resistant depression and major depressive disorder with suicidal thoughts in adults. Treatment is administered in a supervised clinical setting by a qualified Clinician to ensure safety and proper monitoring.

If you've tried multiple antidepressant medications without adequate response, you may be a candidate for this innovative depression treatment. Results vary, and treatment plans are personalized.

Curious whether Spravato could be right for you? Speak with a healthcare provider to learn more about your options.

04/22/2026

How Spravato Works: A Different Approach to Depression Treatment

When traditional antidepressants haven't provided relief, it can feel like there's nowhere left to turn. Spravato (esketamine) offers a different path forward.

Unlike typical antidepressant medications that target serotonin or other neurotransmitters, Spravato works by blocking the NMDA receptor in the brain. This unique mechanism may help reset neural pathways associated with depression, potentially offering relief for those living with treatment-resistant depression or major depressive disorder with suicidal thoughts.

Spravato is an FDA-approved nasal spray administered in a clinical setting under the supervision of a qualified Clinician. Treatment sessions are monitored to ensure safety and comfort.

If you've struggled to find effective depression treatment, you may be a candidate for Spravato. Learn more about whether this innovative option could be right for you.

Consult with a healthcare provider to discuss your options.

04/20/2026

What to Expect During Your Spravato Treatment Experience

If you've been researching depression treatment options, you may have heard about Spravato (esketamine) – an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal thoughts. But what is the actual treatment experience like?

Spravato works differently than traditional antidepressants by targeting the NMDA receptor in your brain, offering a new approach when other medications haven't provided relief.

During treatment, you'll self-administer the nasal spray under medical supervision at a certified treatment center. Each session lasts about 2 hours, including monitoring time afterward. Many patients describe feeling relaxed during treatment, and effects can be noticeable within hours to days.

Unlike conventional antidepressant alternatives that may take weeks to work, Spravato offers a faster potential path to symptom relief. Most patients continue with ongoing maintenance treatments as part of their comprehensive mental health care plan.

If traditional depression treatment hasn't worked for you, esktamine therapy like Spravato may be worth exploring. Schedule a consultation with a healthcare provider to discuss whether Spravato is right for your treatment-resistant depression.

04/15/2026

Tired of waiting weeks for a 15-minute visit with your clinician? There's a better way—and now it's more affordable than ever! 💡

Starting January 1, 2026, Direct Primary Care memberships are officially HSA-eligible! This means you can use your Health Savings Account to pay for personalized, unlimited access to your clinician with tax-free dollars.

Here's why this is a game-changer:
✅ No insurance middlemen = longer visits (45-60 minutes vs. 15)
✅ Same-day or next-day appointments
✅ 24/7 direct access to your clinician via phone/text
✅ 40% fewer specialist referrals needed
✅ 65% reduction in ER visits

Unlike concierge medicine with its hefty price tags, DPC typically costs just $50-150/month per person—and now you can pay with pre-tax HSA funds up to $150/month for individuals or $300/month for families.

Perfect for gig workers, small business owners, families with high-deductible plans, or anyone who wants real relationships with their healthcare provider—not rushed visits dictated by billing codes.

📍 Find a DPC practice near you and experience what personalized healthcare should feel like. Your health deserves more than 15 minutes.

👉 Message us to learn how DPC can work with your current insurance plan!